88,216 The Cooper Companies, Inc. $COO Shares Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lifted its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 84.6% during the third quarter, Holdings Channel.com reports. The firm owned 192,454 shares of the medical device company’s stock after buying an additional 88,216 shares during the period. Nisa Investment Advisors LLC’s holdings in Cooper Companies were worth $10,879,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. bought a new position in Cooper Companies in the 2nd quarter worth approximately $1,077,762,000. Generation Investment Management LLP acquired a new position in Cooper Companies during the 2nd quarter worth $356,304,000. Jupiter Topco LLC acquired a new position in Cooper Companies during the 2nd quarter worth $305,074,000. JANA Partners Management LP boosted its position in Cooper Companies by 0.5% in the 2nd quarter. JANA Partners Management LP now owns 3,582,480 shares of the medical device company’s stock valued at $256,900,000 after buying an additional 17,322 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in Cooper Companies by 3.1% in the 2nd quarter. Wellington Management Group LLP now owns 3,468,951 shares of the medical device company’s stock valued at $248,758,000 after buying an additional 103,044 shares during the last quarter. 24.39% of the stock is owned by institutional investors.

Cooper Companies Trading Up 4.5%

COO opened at $61.65 on Friday. The firm’s fifty day moving average is $62.09 and its two-hundred day moving average is $65.80. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.73 and a current ratio of 1.22. The firm has a market cap of $11.72 billion, a PE ratio of 21.04, a price-to-earnings-growth ratio of 2.40 and a beta of 0.83. The Cooper Companies, Inc. has a twelve month low of $51.01 and a twelve month high of $89.83.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.03. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The company had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the previous year, the business earned $0.49 EPS. The firm’s revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities research analysts anticipate that The Cooper Companies, Inc. will post 4.53 EPS for the current year.

Cooper Companies announced that its board has initiated a share repurchase program on Wednesday, September 9th that allows the company to repurchase $3.00 billion in shares. This buyback authorization allows the medical device company to buy up to 22.7% of its stock through open market purchases. Share buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

COO has been the subject of several research reports. Bank of America reissued a “neutral” rating and issued a $65.00 target price (down from $80.00) on shares of Cooper Companies in a research note on Thursday, September 10th. UBS Group cut their price target on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating on the stock in a research note on Thursday, September 10th. Weiss Ratings upgraded Cooper Companies from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, September 18th. JPMorgan Chase & Co. lowered their price objective on Cooper Companies from $71.00 to $58.00 and set a “neutral” rating for the company in a research report on Thursday, September 10th. Finally, Needham & Company LLC dropped their price objective on Cooper Companies from $86.00 to $73.00 and set a “buy” rating for the company in a report on Thursday, September 10th. Four investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $68.60.

Insiders Place Their Bets

In other Cooper Companies news, Director Paul Keel bought 4,701 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was purchased at an average cost of $53.18 per share, with a total value of $249,999.18. Following the completion of the purchase, the director owned 4,701 shares in the company, valued at approximately $249,999.18. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Walter Rosebrough, Jr. purchased 7,000 shares of the stock in a transaction on Friday, September 11th. The stock was acquired at an average price of $54.11 per share, with a total value of $378,770.00. Following the completion of the acquisition, the director directly owned 17,000 shares of the company’s stock, valued at approximately $919,870. This represents a 70.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have acquired 34,701 shares of company stock worth $1,880,039. Corporate insiders own 2.08% of the company’s stock.

About Cooper Companies

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women’s health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women’s health.